Exchange Traded Concepts LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 12.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,750 shares of the medical device company’s stock after selling 1,526 shares during the period. Exchange Traded Concepts LLC’s holdings in DexCom were worth $836,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of DXCM. Geode Capital Management LLC lifted its position in shares of DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Groupama Asset Managment boosted its position in shares of DexCom by 1.1% in the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after acquiring an additional 31,358 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in DexCom by 11.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after acquiring an additional 288,381 shares during the period. 97.75% of the stock is currently owned by institutional investors.
DexCom Stock Up 0.9 %
NASDAQ DXCM opened at $88.30 on Wednesday. The stock’s 50 day simple moving average is $79.73 and its 200 day simple moving average is $76.70. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market cap of $34.49 billion, a PE ratio of 52.87, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.
Insider Transactions at DexCom
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on DXCM. Royal Bank of Canada reduced their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group increased their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Citigroup raised their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Raymond James lowered their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $99.29.
View Our Latest Analysis on DexCom
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
See Also
- Five stocks we like better than DexCom
- Stock Analyst Ratings and Canadian Analyst Ratings
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Low PE Growth Stocks: Unlocking Investment Opportunities
- What Does the Future Hold for Eli Lilly?
- 5 Top Rated Dividend Stocks to Consider
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.